The work was aimed to develope the meter dose formulation of pediatric xylometazoline nasal spray formulation. The 3 2 factorial design was utilized for development of the pediatric formulation. The independent factors were sodium cholate (X 1 ) and Polyethyleneglycol 400 concentration (X 2 ). The optimized formulation composition consisted of 0.105 g sodium cholate and 1.35 ml polyethyleneglycol 400. The formulation was evaluated for solution parameters like drug content, pH, viscosity, % diffusion, sterility and spray evaluation parameters like spray content uniformity, pump delivery, spray pattern, and weight loss. The results for spray content uniformity were in the range of 95-102 %, while pH in the range of 6.5 ± 0.3. The ovality of spray was 1.118, while perimeter and area of spray pattern were found to be 57.42 mm and 258.8 mm 2 respectively for optimized formulation. The least value for repriming was 97.6 % while the extreme value was 102.2 % indicating one actuation was satisfactory for repriming. The results for droplet size test were obtained in the range of 51.63 to 58.90 µm. The formulation along with its container closure was evaluated for its stability up to 12 months at long term conditions. The formulated batch PFE showed better performance for in-vitro drug release with marketed product thus providing another option for treatment of nasal congestion. 
INTRODUCTION
The pharmaceutical arena is constantly in search for novel drug delivery systems that can overwhelm the existing issues. The suitability of administration and enhanced patient amenableness are essential in the strategy of nasal drug delivery system. 1, 2 About 2% of the drugs that are conveyed through nasal route due to the reason for availability of large surface area. In comparison to alternative routes of drug delivery, nasal route is found more prominent. 3,4, 5. There is wide range of differences observed between adults and children in various aspects of pharmacotherapy which are mandatory for achieving accurate and safe dosage administration. The drug product formulated for pediatric use must take into consideration factors such as age targeted, physiological conditions and type of requirement of treatment. Some advancement in development of pediatric formulations is observed due to new regulations, as well as collaborative research work. Allergic rhinits or sinusitis has one indication as nasal congestion in pediatric patients. 6 Drug substance like xylometazoline, which is of imidazole class, acts on alpha-adrenergic receptors of nasal mucosal arterioles leading to decrease of blood flow. It reduces the swelling of nasal turbinate's, relating to amplification of nasal lumen. 7, 8, 9 Various excipients were used in novel drug delivery system with aim of taking specific roles in drug delivery system such as carriers, bioavailability enhancers, masking of taste,
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[356] CODEN (USA): JDDTAO stabilizer, solubilizer etc. In recent days, various natural as well as synthetic polymers are widely used in nasal drug delivery. The present work described the formulation development and evaluation of nasal solution dosage form for pediatric use of xylometazoline as a model drug. The meter dose spray formulation helps to deliver known amount of formulation.
MATERIALS AND METHODS

Materials
Xylometazoline hydrochloride was procured from Anish Chemicals, Gujarat, India. Sodium cholate from National Chemicals Pvt. Ltd, Vadodara, India, PEG 400 from Sigma Aldrich, USA. Methyl Paraben from S.D. Fine Chem. Ltd, Mumbai, India and Sodium carboxymethyl cellulose from Amar cellulose industries, Gujarat, India. The container closure system was obtained from Aptar Pharma, Mumbai, India.
Methods
Preparation of Xylometazoline pediatric nasal solution:
The pediatric nasal solution was prepared by sequential mixing of various excipients as shown in Figure 1 .
Figure 1: Method of preparation of nasal solution
Experimental Design
A 3 level 2 factors factorial design (3 2 ) was adopted using concentration of sodium cholate (X 1 ) and PEG 400 (X 2 ) as independent variables for formulation development of pediatric xylometazoline nasal solution.
(Stat-Ease Design Expert®, v 9). The levels of independent variables were designated as depicted in Table 1 and all the batches were formulated conferring to experimental design ( Table 2) . The batches were then assessed for different parameters. Where Y = dependent variable β0 = Intercept (arithmetic mean of all the batches) runs, β1 = estimated coefficient for the factor X1. Β2-Estimated coefficient for the factor X2 Β12= Estimated coefficient of the interaction between X1 and X2 * Each factorial design batch contained 10 mg of xylometazoline, 0.01 g of Na CMC, 0.15 ml of Glycerin, 0.0033g Methyl Paraben, q.s. of NaCl, and volume was made with purified water to 10 ml Evaluation parameters of formulation:
Clarity:
The formulated solutions were evaluated as in-house test for clarity. The color and clarity were visually examined against black and white surface in inspection booth.
10
Drug Content:
The drug content of the nasal formulation was measured using standard curve equation obtained by calibration curve using UV spectrophotometer at 268 nm. The sample of the formulation was diluted using distilled water and absorbance was measured at 268 nm using water as blank. The mean of three results was used as drug content of the sample. 
pH:
The pH was measured in triplicate for pH using digital pH meter. The model pH range of nasal formulations was in range of 6.5 ± 0.3.
12,13,14
Viscosity:
Viscosity has influence on the dwelling time of formulation, which is associated to rate of drug absorption through nasal mucosa. The viscosity was measured through Brookfield Viscometer (Spindle no S18 at 100 rpm) (Brookfield Viscometer, Model no DV-II PRO, Dolphine instrument, Mumbai).
10
Spray Content Uniformity:
The spray content uniformity as critical parameter for nasal spray, was studied to explore the spray discharged containing the amount of active ingredient from the nosepiece. The examination was carried out for multiple spray form single container and in different container for the same. The acceptance criteria was defined as the amount of active ingredient not outside of 80-120 percent of label claim for more than 1 of 10 containers, none of the determinations is outside of 75-125 percent of the label claim, and the mean is not outside of 85-115 percent of label claim.
15,16
Pump Delivery:
The pump delivery is crucial parameter interrelated with spray content uniformity for product performance. The pediatric nasal spray formulation was assessed for pump-to-pump reproducibility and the pump metering capability. The formulation was actuated for 10 times in a pre-weighed bottle. The bottle was reweighed after 10 actuations and the difference was calculated. 
Weight Loss:
The weight loss is parameters that determines the product performance and stability. Inverted and Horizontal positions shows noteworthy role in weight loss, hence both orientations were kept for the drug product storage. The weight loss of formulation in the container closure system was determined as per USP chapter <755> and it is essentially to be in accordance with the predefined specification.
11,15,17
Priming and Repriming:
The first priming essentially to demonstrate the minimum amount of drug released from the product, while repriming shows the ability of product to delivery same amount of drug content after storage of product. The length of storage for conducting the study is defined as 5, 10 and 30 days. The number of actuations are determined that are required for priming until the subsequent doses meet the specification limits (80-120 % label claim). The number of actuations are determined that are required for re-priming up to the subsequent doses meets the specification limits.
11, 16
In-vitro Diffusion:
This study was performed using the Franz diffusion cell, where recently isolated sheep nasal mucosa obtained from a local slaughter house was utilized for attachment on diffusion chamber. The doner medium comprised of formulation, while the receptor medium comprised of phosphate buffer, while the temperature of the medium was maintained at 37 o C ± 1 o C. 
Droplet Size Distribution:
The deposition of the nasal formulation in cavity is impacted by droplet size distribution of the spray. The delivery device and the formulation are the two major factors that influence the droplet size. There must be appropriate control for droplet size distribution of the delivered plume. The droplet size distribution can be measured in terms of D10, D50, and D90 by utilization of laser diffraction.
21,22
Sterility:
Sterility is an important requirement for nasal formulation. The method used was as per USP chapter for sterility tests <71>.
23
Stability study:
The stability studies were executed at 25 ± 2 o C/ 60 ± 5% RH for stability stations 3, 6, 9 and 12 months for long term studies, while at 40 ± 2 o C/ 75 ± 5% RH for accelerated studies at stations 3 and 6 months. 24 
RESULTS AND DISCUSSION
Preliminary trials and composition of nasal formulation
The preliminary formulation trials were designed for the selection of surfactant concentration, and co-solvent amount. The preliminary parameters like clarity, pH, drug content, % diffusion at 10 minutes and viscosity were optimized by varying one parameter at a time, while keeping the others constant, so that the effect of varied parameter could be evaluated. The concentration range 0.02 g to 0.12 g of sodium cholate as surfactant was selected, while the concentration range of 0.50 ml to 1.50 ml of polyethylene glycol 400 was selected for further studies.
Experimental design
Pediatric nasal solution was formulated by utilizing 3 2 factorial design. These batches were assessed using polynomial equation of design and two check point batches were confirmatory for authentication of design of experiment. The assessment tests parameters consisted for appearance, pH, viscosity, drug content and % diffusion at 10 minutes (Table 3 ). The % diffusion at 10 minutes and viscosity displayed differences based on the values of independent variables, henceforward they were defined as dependent parameters. 
Among the independent variables, X 1 had prominent positive effect (β 1 = 13.1666) on diffusion at 10 minutes. The X 2 variable had very less effect (β 2 = 0.7777), while the interaction between X 1 and X 2 showed no impact on diffusion at 10 minutes (β 12 = 0.00). Sodium cholate exhibited prominent impact on % diffusion at ten minutes. The contour and surface response plot for % diffusion at 10 minutes were displayed in Figure 2 . It could be inferred from the contour and response surface plot that excipient sodium cholate has correlation to % diffusion at 10 minutes.
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[359] CODEN (USA): JDDTAO The data of model summary statistic for % diffusion at 10 minutes (Y 1 ) clearly suggest the quadratic model shows better suitability as compared to other statistic models. The Table 4 displays the independent variables impact on the percentage diffusion at 10 minutes. The data obtained reveals that the p-value < 0.05 stating that the factor has significant impact on dependent parameter. Hence conclusion can be derived that sodium cholate have substantial impact on diffusion rate on formulation. 
The quadratic model shows the enhanced fitting related to other models. The influences of independent factors were as evaluated as displayed in Table 5 . The p value of the model was found (P = 0.0168) < 0.05 indicating that the model was significant. The independent variable X 2 , had prominent positive effect (β 2 = 2.9444) on viscosity, while the X 1 variable had very minor impact (β 1 = 0.3333) viscosity. The changing of factor (PEG 400) X 2 from -1 to +1 showed the viscosity change from 13 cp to 21 cp.
The contour and surface plot for viscosity were constructed as represented in Figure 2 . It can be interpreted that concentration of PEG 400 and viscosity of the formulation were interrelated.
[360] CODEN (USA): JDDTAO The Table 6 displayed the percentage error observed between the experimental value and the predicted value of various experimental batches. The % bias value of diffusion at 10 minutes was found in the range of -1.72% to 1.67 % and the % bias value for viscosity was found in the range of -5.64% to 6.52 %. The percentage bias/error for both the variables were found satisfactory, which endorsed the model selected was successful to predict the response of the experimental design. The summary of the results of regression analysis of batches of xylometazoline nasal solution for full and reduced model was provided in Table 7 . 
Optimization of experimental design
The design of experimental model was validated by two check point batches. The verification for % diffusion and viscosity of checkpoint batches was confirmed by utilizing mathematics equation (3, 4) .
The Table 8 depicts the results for check point batches for % diffusion at 10 minutes and viscosity. The Figure  2 displays contour and surface response plots. The optimization of formulation was performed by utilizing the Design ® Expert software by using desirability approach (Figure 3) .
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[361] CODEN (USA): JDDTAO The optimized formulation contained sodium cholate 0.105 g and PEG 400 1.35 mL as displayed in Table 9 . This formulation PFE displayed values for % diffusion at 10 min and viscosity is 87.33 % and 19.33 cps respectively. The comparision of in-vitro diffusion results between otrivin ® pediatric and batch PFE is revealed in Figure 4 , indicating that the optimized formulation demonstrating superior % diffusion at 10 minutes. (Refer supplementary Table 2 ). The formulation pH for factorial design batches was found in the range of 6.50 ± 0.3 showing better compatibility at the delivery site.
Spray Content Uniformity:
The formulations must be assessed in its relationships of emitted dose content uniformity. The Table 10 data indicated the drug substance content sprayed within same container and among the different containers. The results are in the range of 95-102 %. # indicates different sprays (S1, S2 and S3) from container PC5.
Pump Delivery:
The relevant performance from pump is primarily essential for precise delivery of drug to targeted part. This test guarantees specific dose is constantly delivered by the pump. The initial weight of filled nasal spray was 15 g. The final weight of spray system was found the 14.5 g after 10 actuations, with the actuation volume for each spray as 100 μl. The results showed that the pump delivery of xylometazoline nasal spray formulation for pediatric use was satisfactory.
Spray Pattern:
The pumping performance can be estimated with the help of spray pattern test. This test could be impacted by factors such as the size and shape of the nozzle of pump, the design of the pump, the formulation characteristics etc. The ovality of spray was 1.118, while perimeter and area of spray pattern were found to be 57.42 mm and 258.8 mm 2 respectively. Image actuation graph, along with intensity graph for the formulation are as presented in Figure 5 . The figure 4 endorses that the pump delivered the required medication appropriately without any concerns.
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[363] CODEN (USA): JDDTAO The formulation was stored in both i.e. inverted and horizontal position. Weight loss study was performed for stability time points of 3 and 6 months. As shown in Table 11 , the results indicated that there was no any change for weight loss study demonstrating the reliability of packaging components. These studies were executed to support the number of actuations to be suggested which essentially to be fired to discarded prior to the end user using the product for the first time and subsequent use afterwards. The priming study was performed on formulation nasal spray and the results obtained were 101.2 % and 98.1 % respectively for first actuation. This study referenced that only one actuation requirement as priming since the results obtained were higher than 95 %.
Repriming study:
Repriming study results at 5 days, 10 days and 30 days are as shown in Table 12 . The least value for repriming within 5, 10 and 30 days was obtained to be 97.6 % while the extreme value acquired was 102.2 %. It was concluded that one actuation was satisfactory for repriming. The droplet size study was performed based on laser diffraction method. The instrument used was automatatic nasal actuator (Malvern Instruments,UK) further assembled onto spraytech. The droplet size distribution was carried out for five containers labelled C1 to C5, where each container was actuated at 3 cm distance from orifice of actuator. Single scan was used for performing droplet size distribution at fully developed spray stable phase. The results of median droplet size (D50) mean from 6 cm actuation distance are shown in Table 13 . The results were obtained in the range of 51.63 to 58.90 µm. 
Sterility:
The sterility test of optimized formulation batch PFE was carried out as per USP criteria using container PC8. The sterility test showed no microbial growth, which indicated that the formulation was sterile.
Stability Studies:
The stability of optimized pediatric nasal formulation (Batch PFE) was carried at 25 ± 2 ºC / 60 ± 5% RH for 12 months and accelerated condition study was performed at 40 ± 2 o C/ 75 ± 5% RH for 6 months. The results were displayed in Table 14 . No significant change was observed in context of initial results. Batch number PFE also demonstrated the satisfactory appearance, pH, in vitro diffusion, viscosity and sterility at the completion of the stability study. 
CONCLUSION
The pediatric nasal spray formulation was developed by utilizing factorial design approach. The drug-excipient compatibility study endorsed no interaction between xylometazoline and the excipients. The 3 2 full factorial design was utilized, where sodium cholate (X 1 ) and PEG 400 (X 2 ) were allocated as independent factors. The parameters for solution formulation such as drug content, pH, viscosity, % diffusion, sterility and spray evaluation like spray content uniformity, pump delivery, spray pattern, and weight loss were evaluated. The results for spray content uniformity were in the range of 95-102 %, while pH in the range of 6.5 ± 0.3. The ovality of spray was 1.118, while perimeter and area of spray pattern were found to be 57.42 mm and 258.8 mm 2 respectively for optimized formulation. The least value for repriming was 97.6 % while the extreme value was 102.2 % indicating one actuation was satisfactory for repriming. The results for droplet size test were obtained in the range of 51.63 to 58.90 µm. The formulation along with its container closure was evaluated for its stability up to 12 months at long term conditions. The formulated batch PFE showed better performance for in-vitro drug release with marketed
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[365] CODEN (USA): JDDTAO product thus providing another option for treatment of nasal congestion.
